On (b)(6) 2020, an eye care provider (ecp) in (b)(6) reported a patient (pt) experienced ¿corneal damaged¿ after wearing an acuvue® vita¿ brand contact lens.No further information was provided.On 31jul2020, additional information was received from the pt: the pt reported experiencing blurry vision in the right eye (od) on the third day of wearing the cl ((b)(6) 2020).The pt experienced foreign body sensation upon removal of the contact lens.The pt visited the doctor and was diagnosed with ¿corneal rupture.¿ the pt was prescribed: recombinant human epidermal growth factor eye drops to use 1-2 drops, 6-8 times a day; compound tropicamide eye drops to use 1 drop every 5 minutes, 4 times and then discontinue; tobramycin eye drop to use 1-2 drops, 2-3 times a day; ofloxacin eye ointment to use 2-3 times a day.The pt returned to the doctor for a follow-up on (b)(6) 2020 and was advised to continue using recombinant human epidermal growth factor eye drops 6-8 times a day but can reduce the amount of other eye drops (unspecified).No further information was provided.Multiple attempts have been made to contact the pt to obtain additional information.No further information has been received.The suspect od contact lens was discarded.A lot history review was performed and revealed the following: the batch record did not show any abnormalities in monomer and solution testing.All parameters tested were within specification.All sterilization requirements were successfully completed.Lot b00v442 was produced under normal conditions.If any further relevant information is received, a supplemental report will be filed.
|